| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Teicoplanin complex targets the bacterial cell wall by binding to the D-alanyl-D-alanine terminus of growing peptidoglycan chains. This binding inhibits transglycosylation and transpeptidation reactions, blocking cell wall synthesis and leading to bacterial cell death. The complex is effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis.
|
|---|---|
| ln Vitro |
In HEK293T cells, 2019nCoV-Spike virus in A549 cells, and SARS-CoV-2 virus in Vero E6 cells, tecoplanin sodium has antiviral action. The IC50 values are 0.39, 1.66, and 15.7 µM, respectively [1]. With an EC50 value of 17 µM, tecoplanin sodium suppresses the HIV-1 virus in human CEM cell cultures [1]. It works by interacting with the enzyme through the lipophilic portion of teicoplanin sodium. The anti-MRSA action of tecoplanin sodium is demonstrated by its MIC value of 0.5 mg/L against MRSA ATCC 43300 [2].
In vitro, teicoplanin complex demonstrates potent antibacterial activity against a broad range of Gram-positive bacteria. It is effective against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis. The compound's activity is assessed by determining minimum inhibitory concentrations (MIC) using broth microdilution or agar dilution methods. The complex shows good activity against resistant Gram-positive pathogens. |
| ln Vivo |
In a mouse model of MRSA infection, tecoplanin (10, 30 mg/kg; iv) showed dose-dependent decreases in total mushroom density [2].
In vivo, teicoplanin complex is used as an antibacterial agent for the prophylaxis and treatment of serious infections caused by Gram-positive bacteria. It is effective against infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis. The complex is administered intravenously or intramuscularly. Its long half-life allows for once-daily dosing in clinical settings. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for teicoplanin measure its binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors. The binding affinity is assessed using surface plasmon resonance or other biophysical methods. The compound's ability to inhibit transglycosylation and transpeptidation reactions is measured using in vitro peptidoglycan synthesis assays with purified enzymes or membrane preparations.
|
| Cell Assay |
In vitro cell-based assays for teicoplanin use bacterial cultures of Gram-positive strains. Minimum inhibitory concentrations (MIC) are determined using broth microdilution methods according to CLSI guidelines. The compound's activity against methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis is assessed. Bactericidal activity is evaluated by subculturing onto drug-free media to determine the minimum bactericidal concentration (MBC).
|
| Animal Protocol |
Animal/Disease Models: 20-30 g, male CD1 mice (2 * 106 cfu/ mL MRSA (43 300) 50 µL; mouse thigh infection model) [2]
Doses: 10, 30 mg/kg Route of Administration: intravenous (iv) (iv)injection ; Results every 12 hrs (hrs (hours)): It shows that the total bacterial density decreases in a dose-dependent manner, the dose ≥10 mg/kg/day can achieve the total bactericidal effect, and the dose ≥30 mg/kg/day can inhibit drug resistance. In vivo animal models for teicoplanin include mouse models of Gram-positive bacterial infection. Animals are infected with pathogenic bacteria such as Staphylococcus aureus or Enterococcus faecalis and treated with teicoplanin at various doses. Efficacy is evaluated by measuring bacterial load in target tissues, survival rates, and clinical signs of infection. Pharmacokinetic studies in rodents measure drug absorption, distribution, metabolism, and excretion. |
| ADME/Pharmacokinetics |
Teicoplanin complex has a molecular weight of approximately 1879 for the A2-2 component. The compound is soluble in ethanol, methanol, DMF, DMSO, and water. It is stored at -20°C. Two metabolites have been isolated after intravenous administration of radiolabeled teicoplanin. The compound is administered intravenously or intramuscularly in clinical settings.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Teicoplanin has not been approved for marketing by the U.S. Food and Drug Administration (FDA), but it is available in other countries. Limited data suggest that very little teicoplanin is excreted into breast milk. Because teicoplanin is not absorbed orally, it is unlikely to have adverse effects on breastfed infants. One infant was safely breastfed while the mother was receiving teicoplanin and ceftriaxone. Breastfed infants should be monitored for gastrointestinal upset, such as diarrhea, especially in newborns and preterm infants, until more information becomes available. ◉ Effects on Breastfed Infants A mother who exclusively breastfed her 52-day-old infant developed a soft tissue infection. She received intravenous teicoplanin at 400 mg every 12 hours for three days, followed by 400 mg daily for five days; simultaneously, she received intravenous ceftriaxone 1 g daily; and applied mupirocin cream twice daily. Careful follow-up showed that her baby did not experience any adverse reactions. The toxicity profile of teicoplanin is generally favorable. Common adverse effects include local reactions at the injection site, rash, and gastrointestinal disturbances. Nephrotoxicity and ototoxicity are rare but have been reported. The compound is contraindicated in patients with known hypersensitivity to glycopeptide antibiotics. Drug interactions may occur with nephrotoxic agents. |
| References | |
| Additional Infomation |
Teicoplanin has been reported to be present in both Streptomyces albidoflavus and Streptomyces coelicolor, and relevant data are available. Teicoplanin is a glycopeptide antibiotic complex isolated from Actinoplanes teichomyceticus. Teicoplanin inhibits peptidoglycan polymerization, thereby inhibiting bacterial cell wall synthesis and leading to cell death. (NCI04) The lipoglycopeptide antibiotic in Actinoplanes teichomyceticus is active against Gram-positive bacteria. It consists of five main components, each with a different fatty acid moiety.
Teicoplanin complex is a mixture of glycopeptide antibiotics produced by Actinoplanes teichomyceticus. It is also known as Antibiotic 8327A. The complex is effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis. It is used for the prophylaxis and treatment of serious infections caused by Gram-positive bacteria. Teicoplanin is used for research purposes and is not for human use. |
| Molecular Formula |
C88H97CL2N9O33
|
|---|---|
| Molecular Weight |
1879.6703
|
| Exact Mass |
1877.556
|
| CAS # |
61036-62-2
|
| Related CAS # |
Teicoplanin sodium;184539-13-7
|
| PubChem CID |
133065662
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Index of Refraction |
1.754
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
24
|
| Hydrogen Bond Acceptor Count |
34
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
132
|
| Complexity |
3920
|
| Defined Atom Stereocenter Count |
22
|
| SMILES |
CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O
|
| InChi Key |
BJNLLBUOHPVGFT-CAYRISATSA-N
|
| InChi Code |
InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
|
| Chemical Name |
(1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL DMSO : ~25 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 120 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5320 mL | 2.6600 mL | 5.3201 mL | |
| 5 mM | 0.1064 mL | 0.5320 mL | 1.0640 mL | |
| 10 mM | 0.0532 mL | 0.2660 mL | 0.5320 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
